TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31258137
Drug: 3-day combined
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3-day combined diet (CMD) + sulfate free polyethylene glycol and electrolyte lavage solution (SF-PEG-ELS)
Study: 30092197
Drug: Narrow-spectrum antibiotics
Normalized name: Sentinel Spectrum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Narrow-spectrum antibiotics (vancomycin)
Study: 30092197
Drug: Broad-spectrum antibiotics
Normalized name: Sentinel Spectrum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Broad-spectrum antibiotics (oral vancomycin, ciprofloxacin, metronidazole)
Study: 26946732
Drug: Bloodletting pricking,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bloodletting pricking, cupping, and surrounding acupuncture treatment, given once a day and once every other day after the first 3 days for a total of one week.
Study: 26946732
Drug: Intravenous drip
Normalized name: DRIP COLLECTOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous drip of acyclovir and oral administration of vitamin B1 and B12, once a day for a total of one week.
Study: 22763905
Drug: 5 mL/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mL/kg acetated Ringer's solution
Study: 22763905
Drug: 10 mL/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL/kg acetated Ringer's solution
Study: 21378348
Drug: S-1 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 (50 mg)
Study: 21378348
Drug: FT (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: FT (800 mg)
Study: 17389005
Drug: Unopposed oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unopposed oral 17beta‐estradiol
Study: 16277792
Drug: Walnut-supplemented diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Walnut-supplemented diet (35 g daily)
Study: 7601294
Drug: Anxiolytic (fludiazepam)
Normalized name: ANXIOLYTICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anxiolytic (fludiazepam) for 12 weeks
Study: 2088109
Drug: 4 ml
Normalized name: ethanol 1.4 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 ml mixture including 3 ml of 0.5% bupivacaine, 0.2 mg adrenaline
Study: 2088109
Drug: 4 ml
Normalized name: ethanol 1.4 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 ml mixture including 3 ml of 0.5% bupivacaine, 0.15 mg clonidine
Study: 440849
Drug: Decongestant-antihistamine mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decongestant-antihistamine mixture
Study: 25254938
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg tamsulosin and 50 mg mirabegron daily for 8 weeks
Study: 25254938
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg tamsulosin daily for 8 weeks
Study: 12915681
Drug: Furosemide (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide (20 mg/d)
Study: 10596522
Drug: Group cognitive-behavioral
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group cognitive-behavioral therapy (GCBT) with concurrent parent sessions
Study: 8735854
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate aqueous nasal spray (FPANS) 200 micrograms once daily
Study: 8735854
Drug: Oral fluticasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral fluticasone propionate 5 mg or 10 mg once daily
Study: 8735854
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate aqueous nasal spray (FPANS) 200 micrograms once daily for 1 year
Study: 29217387
Drug: Individualised duration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualised duration of elastic compression therapy
Study: 30314712
Drug: Standard duration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard duration of elastic compression therapy
Study: 25643766
Drug: Propofol-remifentanil combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol-remifentanil combination
Study: 25643766
Drug: Dexmedetomidine-remifentanil combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine-remifentanil combination
Study: 23258191
Drug: Individually tailored
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individually tailored physical and daily activities
Study: 23258191
Drug: Individually tailored
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individually tailored physical and daily activities (more than 150 min/week)
Study: 23258191
Drug: Individually tailored
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individually tailored physical and daily activities (more than 10 weeks)
Study: 19143854
Drug: Solifenacin 5
Normalized name: solifenacin 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solifenacin 5 mg once daily (SOL5)
Study: 19143854
Drug: Solifenacin 10
Normalized name: solifenacin 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solifenacin 10 mg once daily (SOL10)
Study: 19143854
Drug: Tolterodine immediate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolterodine immediate release 2 mg twice daily (TOL4)
Study: 15631608
Drug: Bupropion (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupropion (300 mg/day for 10 weeks)
Study: 3679623
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg naftidrofuryl
Study: 29871368
Drug: 4 mL
Normalized name: ethanol 1.4 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mL ESI
Study: 29871368
Drug: 6 mL
Normalized name: ethanol 0.6 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mL ESI
Study: 29871368
Drug: 8 mL
Normalized name: ethanol 0.8 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mL ESI
Study: 29871368
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (4 mL, 6 mL, 8 mL)
Study: 24846036
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (education and advice, manual therapy, home exercise, gait aid if appropriate)
Study: 24846036
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment (inactive ultrasound and inert gel)
Study: 22551785
Drug: Sorafenib 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib 600 mg b.i.d.
Study: 22551785
Drug: Sorafenib (dose-escalated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib (dose-escalated to 600 mg b.i.d. and 800 mg b.i.d.)
Study: 22551785
Drug: Sorafenib (dose-escalated)
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sorafenib (dose-escalated)
Study: 18798437
Drug: Ketoconazole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole (400 mg) and clindamycin (100 mg) in vaginal tablets
Study: 18798437
Drug: Clindamycin alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin alone (600 mg/daily) orally for six days
Study: 10929164
Drug: Multidimensional preoperative
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multidimensional preoperative intervention including exercise training twice per week, education and reinforcement, and monthly nurse-initiated telephone calls.
Study: 3781322
Drug: Domperidone 10
Normalized name: domperidone 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone 10 mg iv
Study: 24014042
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy for anorexia nervosa (CBT-AN)
Study: 21510830
Drug: Amlodipine 10
Normalized name: amlodipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine 10 mg + Aliskiren 300 mg
Study: 11481401
Drug: apoLFbuf (4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: apoLFbuf (4.5 g bovine LF with gastric pH buffer)
Study: 11481401
Drug: apoLF (4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: apoLF (4.5 g bovine LF without buffer)
Study: 9669008
Drug: bupivacaine-fentanyl (0.125%
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupivacaine-fentanyl (0.125% bupivacaine with 0.005 mg/ml fentanyl)
Study: 9669008
Drug: bupivacaine-morphine (0.125%
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupivacaine-morphine (0.125% bupivacaine with 0.05 mg/ml morphine)
Study: 9669008
Drug: bupivacaine-morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupivacaine-morphine
Study: 3175546
Drug: Packages containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Packages containing suppositories
Study: 3175546
Drug: Packages containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Packages containing capsules or tablets
Study: 3175546
Drug: Six different
Approvals — FDA: no, EMA: no, PMDA: no
Description: Six different packages for suppositories
Study: 23145973
Drug: High fluoride
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High fluoride (≥2 ppm) and heavy force (225 g)
Study: 23145973
Drug: Low fluoride
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low fluoride (≤0.05 ppm) and heavy force (225 g)
Study: 23145973
Drug: High fluoride
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High fluoride (≥2 ppm) and light force (25 g)
Study: 23145973
Drug: Low fluoride
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low fluoride (≤0.05 ppm) and light force (25 g)
Study: 20847092
Drug: Daily administration
Normalized name: Prevpac 30mg-500mg-500mg Daily Administration Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily administration of maintenance prednisolone for 7 days during intercurrent infections
Study: 19650876
Drug: Insulin detemir
Normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Insulin detemir (660 mU/kg, infusion rate 5 mU/kg/min)
Study: 19650876
Drug: Human insulin
Normalized name: Human insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Human insulin (60 mU/kg, infusion rate 2 mU/kg/min)
Study: 19650876
Drug: Insulin detemir
Normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Insulin detemir and Human insulin
Study: 21444871
Drug: Gemcitabine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine plus cisplatin chemoradiotherapy followed by brachytherapy and adjuvant gemcitabine/cisplatin chemotherapy
Study: 21444871
Drug: Cisplatin and
Normalized name: A micelle drug formulation composed of cisplatin and mPEG-poly(l-Glu) diblock copolymer with 1,3-propanediyl linkagecisplatin is incorporated in polymeric micelles via polymer-metal complex formation with cis-geometry of PT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin and concurrent XRT followed by BCT only
Study: 9620099
Drug: Sucralfate 1
Normalized name: sucralfate 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate 1 g every 6 hours
Study: 9620099
Drug: Cimetidine 300
Normalized name: cimetidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 300 mg by intravenous bolus every 8 hours
Study: 9620099
Drug: Cimetidine 900
Normalized name: cimetidine 900 mg-0.9%/500 mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 900 mg by continuous intravenous infusion/24 hours
Study: 2693929
Drug: Letosteine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letosteine (25 mg x 3 g/die for 10 days)
Study: 348546
Drug: Nifedipine (N)
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine (N) 10 mg, oral
Study: 348546
Drug: N +
Normalized name: Lutein + Kale
Approvals — FDA: no, EMA: no, PMDA: no
Description: N + isosorbide dinitrate (ISDN) 10 mg oral
Study: 348546
Drug: N +
Normalized name: Lutein + Kale
Approvals — FDA: no, EMA: no, PMDA: no
Description: N + propranolol (Pr) 40 mg, oral
Study: 348546
Drug: Verapamil 80
Normalized name: verapamil 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil 80 mg oral
Study: 29499289
Drug: Corticosteroid injection
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid injection + 12 weeks of exercise therapy
Study: 29499289
Drug: Placebo injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injection + 12 weeks of exercise therapy
Study: 27991432
Drug: omeprazole/esomeprazole (strong
Approvals — FDA: no, EMA: no, PMDA: no
Description: omeprazole/esomeprazole (strong CYP2C19 inhibitors)
Study: 27991432
Drug: pantoprazole/rabeprazole (weak
Approvals — FDA: no, EMA: no, PMDA: no
Description: pantoprazole/rabeprazole (weak CYP2C19 inhibitors)
Study: 19933908
Drug: Vorinostat (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vorinostat (400 mg by mouth daily) with carboplatin (6 mg/mL x min) and paclitaxel (200 mg/m2 on day 3)
Study: 19933908
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with carboplatin (6 mg/mL x min) and paclitaxel (200 mg/m2 on day 3)
Study: 19933908
Drug: Vorinostat (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vorinostat (400 mg by mouth daily) with carboplatin and paclitaxel
Study: 19933908
Drug: Vorinostat (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vorinostat (400 mg by mouth daily)
Study: 16153271
Drug: Bradykinin (BK)
Normalized name: dimethicone
DrugBank: Bradykinin (DB12126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bradykinin (BK) 5 microg/mL infusion
Study: 12514672
Drug: Conivaptan (vasopressin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conivaptan (vasopressin antagonist)
Study: 10962771
Drug: Daily maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily maintenance doses every 24 hours (4 or 8 mg/70 kg)
Study: 10962771
Drug: Double the
Normalized name: THE-630
DrugBank: THE-630 (DB16750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double the daily maintenance dose every 48 hours (8 or 16 mg/70 kg)
Study: 10962771
Drug: Quadruple the
Normalized name: THE-630
DrugBank: THE-630 (DB16750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadruple the daily maintenance dose every 96 hours (16 or 32 mg/70 kg)
Study: 10962771
Drug: Daily dosing
Normalized name: Osmolex 322 MG Daily Dosing Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dosing regimen
Study: 8553952
Drug: i.v. administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. administration of ultrasmall superparamagnetic iron oxide (USPIO) particle (Code 7227)
Study: 1985710
Drug: Protracted infusional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protracted infusional 5-fluorouracil (5-FU) infusion at 300 mg/m2/d for 10 weeks of every 12 weeks
Study: 1985710
Drug: Protracted infusional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protracted infusional 5-fluorouracil (5-FU) infusion with weekly cisplatin (20 mg/m2)
Study: 1985710
Drug: Protracted infusional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protracted infusional 5-fluorouracil (5-FU) infusion
Study: 1985710
Drug: Protracted infusional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protracted infusional 5-fluorouracil (5-FU) infusion with weekly cisplatin
Study: 30203752
Drug: Cervical paravertebral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cervical paravertebral nerve block combined with Mailuoning and Angelica sinensis injection
Study: 30203752
Drug: Glucocorticoid nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucocorticoid nerve block therapy
Study: 23062767
Drug: Simvastatin 40
Normalized name: simvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 40 mg + Ezetimibe 10/10 mg
Study: 18572078
Drug: Laquinimod 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laquinimod 0.6 mg per day
Study: 18572078
Drug: Laquinimod 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laquinimod 0.3 mg per day
Study: 12415583
Drug: Adalimumab 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab 0.5 mg/kg
Study: 12415583
Drug: Adalimumab 1
Normalized name: adalimumab 100 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab 1 mg/kg
Study: 12415583
Drug: Adalimumab 3
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adalimumab 3 mg/kg
Study: 12415583
Drug: Adalimumab 5
Normalized name: adalimumab 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab 5 mg/kg
Study: 12415583
Drug: Adalimumab 10
Normalized name: adalimumab 100 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab 10 mg/kg
Study: 9836028
Drug: Diltiazem-lidocaine combination
Normalized name: lidocaine, combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem-lidocaine combination (0.3 mg.kg‐1 diltiazem plus 1.5 mg.kg‐1 lidocaine)
Study: 9836028
Drug: Diltiazem (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (0.3 mg.kg‐1)
Study: 7661296
Drug: Local continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local continuous microwave therapy (CM)
Study: 7661296
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (controls)
Study: 2758362
Drug: Daily ingestion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily ingestion of one hens' egg and about 11 of cows' milk
Study: 345735
Drug: 1.5% timolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5% timolol maleate administered twice a day for two weeks
Study: 27874292
Drug: G‐CSF infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF infusion
Study: 27874292
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (opted out of G‐CSF)
Study: 23289762
Drug: Levamisole film-coated
Normalized name: Levamisole
DrugBank: Levamisole (DB00848)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levamisole film-coated tablets
Study: 19051275
Drug: Rational emotive
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rational emotive behavioral therapy (REBT)
Study: 19051275
Drug: Fluoxetine (Prozac)
Normalized name: fluoxetine Oral Capsule [Prozac]
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoxetine (Prozac)
Study: 15115421
Drug: Relaxation/flexibility therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relaxation/flexibility therapy
Study: 9409351
Drug: Clozapine (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clozapine (12.5 mg)
Study: 9409351
Drug: Clozapine (average
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clozapine (average daily dose of 45 +/- 9.6 mg for 15.5 +/- 8.3 months)
Study: 2960579
Drug: Oral-motor treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral-motor treatment
Study: 31196678
Drug: Regenerative cell-based
Normalized name: Regener-Eyes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regenerative cell-based therapy
Study: 16051518
Drug: Atorvastatin 10
Normalized name: atorvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 10 mg/day (n = 14)
Study: 16051518
Drug: Atorvastatin 10
Normalized name: atorvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 10 mg/day plus vitamin E 400 IU/day (n = 12)
Study: 16051518
Drug: No statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: No statin or antioxidant treatment (n = 12, controls)
Study: 12919387
Drug: Oxcarbazepine (OXC)
Normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxcarbazepine (OXC) at a median dose of 2,400 mg/day
Study: 10929216
Drug: Short-term oral
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term oral creatine supplementation (20 g.day‐1 for 6 days)
Study: 2425204
Drug: Galanin infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Galanin infusion at 33.2 pmol/kg/min
Study: 2425204
Drug: Galanin infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Galanin infusion at 7.8 pmol/kg/min
Study: 2425204
Drug: Galanin infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Galanin infusion (both doses)
Study: 23982273
Drug: Oxytocin (26
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxytocin (26 IU intranasal administration)
Study: 21921425
Drug: FBRA (fermented
Approvals — FDA: no, EMA: no, PMDA: no
Description: FBRA (fermented brown rice) 21.0 g/day for 2 weeks
Study: 21921425
Drug: Control food
Normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control food 21.0 g/day for 2 weeks
Study: 11982444
Drug: Dextroamphetamine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextroamphetamine (30 mg)
Study: 10680491
Drug: 1% SD-Ag
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% SD-Ag cream
Study: 2652887
Drug: NaCl without
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaCl without drugs stimulating blood flow (Control)
Study: 20553355
Drug: Nystatin (100,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nystatin (100,000 IU nystatin/g + 20% zinc oxide), n = 46
Study: 18430210
Drug: Continuous ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous ropivacaine 0.75% infusion
Study: 12545149
Drug: Morphine-6-glucuronide (63
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine-6-glucuronide (63 to 112 mg IV bolus, followed by infusion for 1.8 to 6.4 hours)
Study: 12545149
Drug: Morphine (26
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (26 to 66 mg IV bolus, followed by infusion for 1.8 to 6.4 hours)
Study: 10626190
Drug: Nafamostat mesilate
Normalized name: mesylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nafamostat mesilate (2 mg/kg/day) administered during and after the operation for 7 days
Study: 10626190
Drug: Standard post-operative
Normalized name: Sx1 Medicated Post-Operative System KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard post-operative intensive therapies (Control)
Study: 22670856
Drug: Autologous serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous serum (AS) eyedrops diluted at 20%, treatment duration: 2 weeks
Study: 22670856
Drug: Conventional artificial
Normalized name: COLOR,ARTIFICIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional artificial tears, treatment duration: 2 weeks
Study: 18818309
Drug: anti‐CTLA‐4 antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: anti‐CTLA‐4 antibody